Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 non-inferiority study of clotrimazole ovule versus vaginal tablet in vaginal candidiasis
2008-000718-63Phase 3Completed
- Sponsor
- Bayer Consumer Health
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of clotrimazole in vulvovaginal candidiasis (VVC) (2 arms), sponsored by Bayer Consumer Health. Primary endpoints: Overall response at 10–14 days and Overall response at 6–8 weeks. Started May 2009; status: completed.
02
Drugs
clotrimazole
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on 2008-000718-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000718-63.